Applications of 1-(5-Isoquinolinesulfonyl)Piperazine, Dihydrochloride in Industrial Manufacturing

As a specialized manufacturer, we supply 1-(5-Isoquinolinesulfonyl)Piperazine, Dihydrochloride to advanced segments across the pharmaceutical and bioscience industries. This intermediate supports critical reactions in both small molecule synthesis and enzyme inhibition processes. Below, we detail primary downstream sectors, technical integration guidance, and regulatory frameworks where this material is essential for high-quality batch production.

1. Kinase Inhibitor Development for Preclinical Pharmaceuticals

Leading pharmaceutical companies use this compound to synthesize selective kinase inhibitors during target validation and early drug discovery. It serves a crucial role as a sulfonamide moiety provider for isoquinoline scaffolds, directly affecting structure-activity relationships in early-stage candidate molecules. Process chemists incorporate it at slightly varied loads depending on desired potency and probe selectivity, refining usage per route optimization and cell assay results.

Industry compliance standards

• ICH Q7 Good Manufacturing Practice (GMP) for APIs
• 21 CFR Part 211 (FDA cGMP for Finished Pharmaceuticals)
• EU Guidelines for Medicinal Products for Human Use
• OECD Principles of Good Laboratory Practice (GLP)

Typical usage ratio

• 0.8–2.5 molar equivalents relative to heterocyclic core
• Adjusted batchwise based on SAR output and purification needs

Downstream process integration

• Introduced following deprotection of core amines during the late-stage synthetic route
• Purified by preparative chromatography before final product isolation

Final product types

• Tool compounds for kinase screening libraries
• Prototype kinase inhibitor APIs
• Reference standards for bioassays in oncology research

2. Protein Kinase Assays for Enzyme Modulation Research

Principal biochemical reagent suppliers rely on this intermediate to produce high-purity reagents for cell signaling research. Its sulfonylpiperazine core enables irreversible inhibition of serine/threonine kinases in in vitro and in situ assay kits. Controlled use maximizes probe selectivity while minimizing off-target cytotoxicity, with formulation standards centered around batch reproducibility and reagent stability for consistent academic and commercial bioassay outcomes.

Industry compliance standards

• USP General Chapter <1040> Biologics and Biotechnology-derived Products
• ISO 9001:2015 Quality Management Systems
• REACH Registration (if commercialized in the EU)

Typical usage ratio

• 1–5 μM final concentration in assay buffer formulations
• Optimized per kinase isoform and cell line compatibility

Downstream process integration

• Added post-protein expression but pre-activity readout stage
• Aliquoted into single-use assay vials under nitrogen protection

Final product types

• Enzyme inhibitor screening kits for biotech laboratories
• Ready-to-use kinase profiling reagent sets
• Cell signaling pathway research products

3. Small Molecule Drug Intermediate Production (Contract Manufacturing)

Contract manufacturers leverage this sulfonamide intermediate in multi-step custom syntheses for pharmaceutical clients. Its precise integration provides the structural basis for diverse heterocyclic drug candidates, especially in central nervous system (CNS) and oncology indications. QC laboratories routinely monitor purity and residual solvent levels at every step. Usage proportions are engineered into cGMP-compliant protocols, tailored for each registered customer project and scale.

Industry compliance standards

• ICH Q11 Development and Manufacture of Drug Substances
• EDQM CEP Certification for European drug master files
• FDA DMF Submission (Type II)
• ISO 17025 Analytical Laboratory Accreditation

Typical usage ratio

• 1.1–1.4 molar equivalents per final product batch size
• Varied according to process route and downstream impurity profile

Downstream process integration

• Coupled directly in amidation and sulfonation reaction steps
• Subjected to inline HPLC or GC-MS for process monitoring

Final product types

• API intermediate batches for CNS or oncology APIs
• Regulatory submission samples (IND/ANDA/MAA)
• Reference standards for impurity characterization

4. Analytical Standard Preparation for QC and Regulatory Laboratories

Analytical laboratories use the pure salt form as a reference standard for HPLC, MS, and bioassay calibration related to drug substance release programs. Proper handling allows consistent retention time and quantification verification in GMP environments. Preparation adheres to pharmacopeial protocols, with concentration accuracy certified by mass balance and NMR traceability for documented release testing.

Industry compliance standards

• USP/EP Reference Standard Certification
• ISO/IEC 17034 General Requirements for Reference Material Producers
• FDA Analytical Procedure Validation Guidelines

Typical usage ratio

• 10–100 mg per calibration batch, matched to analytical run size and detection system
• Stock solution concentration standardized at 1–5 mg/mL

Downstream process integration

• Dissolved in validated solvents for calibration stock solution production
• Used as external standard in batch release analytical sequences

Final product types

• Traceable reference material kits for pharmaceutical labs
• Analytical standards for quality control and raw material authentication
• Certificate of Analysis-backed release testing samples

5. Structure-Activity Relationship (SAR) Optimization in Medicinal Chemistry

Innovative biotech and medicinal chemistry groups integrate this compound into iterative SAR programs to fine-tune lead molecule pharmacology. The sulfonylpiperazine scaffold expands chemical space and tune selectivity toward isoquinoline-based targets. Chemists control its input by parallel synthesis or solution-phase combinatorial chemistry, balancing yield and new molecule diversity per cycle.

Industry compliance standards

• GLP (Good Laboratory Practice) for Research Development Labs
• Institutional Chemical Hygiene and Safety Plans (OSHA 29 CFR 1910.1450)
• ISO 9001 QMS for R&D facilities

Typical usage ratio

• 0.5–2 molar equivalents per target compound, adjusted per route efficiency and lead evaluation results

Downstream process integration

• Employed during sulfonylation of piperazine derivatives in stagewise analog synthesis
• Pooled into analog libraries for downstream biological screening

Final product types

• Lead molecule analog sets for target validation
• SAR data sets for medicinal chemistry teams
• Advanced chemical tools for patent application support